Ullah Abid, Ahmad Shujaat, Ali Niaz, Rahman Shafiq Ur, Hussain Haya, Alghamdi Saad, Almehmadi Mazen, Dablool Anas S, Bannunah Azzah M, Bukhari Syeda Hajira, Almarshad Feras
Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal, Dir Upper 18000, KPK, Pakistan.
Department of Pharmacology, Institute of Basic Medical Sciences, Khyber Medical University, Peshawar 25100, KPK, Pakistan.
Antibiotics (Basel). 2022 Jan 24;11(2):148. doi: 10.3390/antibiotics11020148.
Fluoroquinolones (FQs) have been reported to cause dysglycemia in both diabetic and non-diabetic patients. However, diabetic patients are usually on polypharmacy, so we cannot attribute the dysglycemia specifically to FQs. To answer the question as to whether and influence blood glucose levels and serum insulin levels or otherwise, rabbits were used as experimental animals in an in vivo model followed by a phase I randomized clinical trial in euglycemic healthy volunteers. The effects on the serum insulin and blood glucose levels in the and treated groups were, respectively, determined on the fifth day in both the in-vivo rabbits model and in the test subjects of the phase I clinical trial. The effects of these drugs were also checked on the histomorphology of the pancreas in the rabbits. The findings of our study suggest that and significantly ( < 0.05) reduced the blood glucose levels via a subsequent significant shift in the serum insulin levels both in the in vivo animal model and in the test subjects of the phase I clinical trial. No prominent effects on the beta cells histomorphology were noted in this study. showed a more significant effect than . The insulinotropic effect was comparable to the effect of . It is concluded that and have a significant blood glucose lowering effect mediated through insulinotropic action. (Clinical Trials.gov identifier: NCT04692623).
据报道，氟喹诺酮类药物（FQs）可导致糖尿病患者和非糖尿病患者出现血糖异常。然而，糖尿病患者通常同时服用多种药物，因此我们无法将血糖异常具体归因于FQs。为了回答[具体药物名称1]和[具体药物名称2]是否影响血糖水平和血清胰岛素水平，或以其他方式产生影响的问题，在体内模型中使用兔子作为实验动物，随后在血糖正常的健康志愿者中进行了一项I期随机临床试验。在体内兔子模型和I期临床试验的受试对象中，分别在第5天测定[具体药物名称1]和[具体药物名称2]治疗组对血清胰岛素和血糖水平的影响。还检查了这些药物对兔子胰腺组织形态学的影响。我们的研究结果表明，在体内动物模型和I期临床试验的受试对象中，[具体药物名称1]和[具体药物名称2]均通过血清胰岛素水平随后的显著变化，显著（P<0.05）降低了血糖水平。在本研究中未观察到对β细胞组织形态学的显著影响。[具体药物名称1]的效果比[具体药物名称2]更显著。促胰岛素作用与[对比药物名称]的作用相当。得出的结论是，[具体药物名称1]和[具体药物名称2]通过促胰岛素作用具有显著的降血糖效果。（临床试验注册号：NCT04692623）
